These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 19644623

  • 21. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 22. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
    Kapral T, Stamm T, Machold KP, Montag K, Smolen JS, Aletaha D.
    Arthritis Res Ther; 2006 Apr; 8(2):R46. PubMed ID: 16507172
    [Abstract] [Full Text] [Related]

  • 23. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 24. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [Abstract] [Full Text] [Related]

  • 25. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 26. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Jan; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 27. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Emery P.
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [Abstract] [Full Text] [Related]

  • 28. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ, Ballina J, Carbonell J, Martín-Mola E, Tornero J, Ramírez E, Galván J.
    Reumatol Clin; 2011 Nov; 7(2):88-93. PubMed ID: 21794790
    [Abstract] [Full Text] [Related]

  • 29. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H, Ohno S, Ishigatsubo Y.
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [Abstract] [Full Text] [Related]

  • 30. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P, Esselens G, Westhovens R.
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [Abstract] [Full Text] [Related]

  • 31. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres.
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [Abstract] [Full Text] [Related]

  • 32. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 33. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.
    Tiippana-Kinnunen T, Paimela L, Kautiainen H, Laasonen L, Leirisalo-Repo M.
    Scand J Rheumatol; 2010 Apr; 39(1):12-8. PubMed ID: 20132065
    [Abstract] [Full Text] [Related]

  • 34. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE, Hong P, Koehler BE.
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [Abstract] [Full Text] [Related]

  • 35. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
    Söderlin MK, Lindroth Y, Turesson C, Jacobsson LT.
    Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
    [Abstract] [Full Text] [Related]

  • 36. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA.
    J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
    [Abstract] [Full Text] [Related]

  • 37. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
    Homer D, Nightingale P, Jobanputra P.
    Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
    [Abstract] [Full Text] [Related]

  • 38. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 39. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
    Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS.
    Rheumatology (Oxford); 2004 Jul; 43(7):906-14. PubMed ID: 15113999
    [Abstract] [Full Text] [Related]

  • 40. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs.
    Wong M, Mulherin D.
    Musculoskeletal Care; 2007 Sep; 5(3):148-59. PubMed ID: 17590885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.